Interview with Jean-Pierre Delwart, Chief Executive Officer, Eurogentec Belgium
Mr Delwart, you have been acting CEO of EuroGenTec for an impressive 19 years. During your tenure, what would you say has been the single most important change in the…
Address: Rue du Bois Saint Jean, 5, 4102 Seraing,Belgium
Tel: +32 4 372 74 00
Web: http://www.eurogentec.com/eu-home.html
Eurogentec S.A., part of Kaneka Corporation, is a leading global supplier of innovative reagents, kits, specialty products and custom services. Through its three inter-related business units (BU), the company provides high quality products to scientists involved in the life science, biotechnology, diagnostic and pharmaceutical markets. Eurogentec is fully ISO 9001, ISO 13485 certified, cGMP accredited by the Belgian Ministry of Health and approved by the US FDA for the commercial manufacturing of a biologic for the US market.
The Life Science Research BU is specialized in innovative solutions in Genomics and Proteomics. Expert in small and large-scale synthesis, Eurogentec proposes a wide range of reagents, kits and consumables for Life Science applications such as Custom Oligonucleotides, high performance PCR/qPCR Kits & Reagents (including high pure Diamond Taq® DNA Polymerases), catalogue dyes, peptides & antibodies. Eurogentec is also specialist in the design and synthesis of custom peptides and production of custom antibodies (including a 28-day Speedy protocol) as well as producing pre-dispensed assays in a GMP environment.
The In Vitro Diagnostics BU provides technical and project support for contract manufacturing of GMP oligonucleotides and Taq DNA polymerases for use in Molecular Diagnostic applications. As a certified ISO 13485 and GMP compliant manufacturer, our manufacturing processes take place in classified clean rooms with controlled processes and full traceability. Our production facilities in Belgium and US enable high quality materials for the in vitro Diagnostic community.
The GMP BioManufacturing BU is a full-service Contract Manufacturing Organization (CMO) and offers significant know-how in process development, technology transfer, formulation, scale-up and manufacturing of GMP proteins, protein conjugates, plasmids and bacterial vaccines for pre-clinical, clinical and commercial uses, all according to FDA and EMA requirements. Experts in microbial production (E. coli, P. pastoris, etc), Eurogentec offers various development strategies based on protein refolding, periplasmic expression, and protein expression by secretion. As a one-stop shop, Eurogentec provides a complete gene to injectable service offering.
Mr Delwart, you have been acting CEO of EuroGenTec for an impressive 19 years. During your tenure, what would you say has been the single most important change in the…
Glenn Vaughan of the British Chamber of Commerce | EU & Belgium discusses the importance of the Belgium-UK relationship, the role of healthcare and the life sciences within that, and…
Romuald Gaudefroy, managing director of CAF-DCF, the Belgian subsidiary of the LFB Group, introduces the company which was integrated into LFB in 2016. Gaudefroy goes on to offer insights on…
Miguel Forte, CEO of Bone Therapeutics, walks through his journey leading the promising Belgian biotech company. He also shares with his view of the Belgian healthcare system and what makes…
Brigitte Nolet, country manager of Roche for Belgium and Luxembourg, speaks about her transition to the Belgian market and her priorities for leading the affiliate. Nolet goes on the elaborate…
Jean Nève and Fabrice Peters, president and general coordinator of the Belgian Superior Health Council (SHC), introduce the organization, elaborate on its role in helping guide the country’s healthcare policy,…
Bertrand Duquesne, managing director of Boiron Belgium, elaborates on the challenges being faced by homeopathy manufacturers in western Europe and explains how the company and its peers are create dialogue…
Vincent Verschraegen, country manager of Mylan Belgium and Luxembourg, speaks about his onboarding in the company and what attracted him to join the organization. Verschraegen also discusses Mylan’s evolution from…
PDC*Line Pharma’s Eric Halioua introduces the Belgian immuno-oncology biotech, its clinical-stage assets, the impact of the firm’s collaboration with Korean LG Chem, and future internationalisation strategies. As a multicultural…
Miranda Heining, general manager of Fresenius Kabi for Belgium and the Netherlands, speaks about the career path that led her to join the pharma industry and lead the affiliate, her…
Christos Andriopoulos, managing director of Merck, speaks about his experience transitioning from global operations to leading a country subsidiary. Andriopoulos goes on to explain the company’s unique positioning as an…
Fréderic Covemaeker, general manager of Nordic Pharma Belgium, introduces the Belgian affiliate which he established himself in 2008 and elaborates on the next stage of development for operations as Nordic…
Despite a population size of only 11.4 million (ninth in Europe), Belgium is the continent’s fifth biggest spender on R&D, behind only Germany, Switzerland, the UK, and France according to…
See our Cookie Privacy Policy Here
